Clinical and genetic drivers of oligo-metastatic disease in colon cancer
Background: Oligo-metastatic disease (OMD) in colon cancer patients exhibits distinct clinical behavior compared to poly-metastatic disease (PMD), with a more responsive and indolent course. This study aims to identify clinical and biological factors uniquely associated with oligo-metastatic behavio...
Saved in:
Main Authors: | Alessandro Ottaiano, Mariachiara Santorsola, Roberto Sirica, Annabella Di Mauro, Antonella Di Carlo, Monica Ianniello, Francesco Sabbatino, Rosa Castiello, Francesca Del Peschio, Marco Cascella, Francesco Perri, Maurizio Capuozzo, Nicola Martucci, Edoardo Mercadante, Valentina Borzillo, Rossella Di Franco, Francesco Izzo, Vincenza Granata, Carmine Picone, Antonella Petrillo, Massimiliano Berretta, Salvatore Stilo, Luca Tarotto, Anna Chiara Carratù, Gerardo Ferrara, Madhura Tathode, Alessia Maria Cossu, Marco Bocchetti, Michele Caraglia, Guglielmo Nasti, Giovanni Savarese |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558624001520 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
High tumor mutational burden assessed through next-generation sequencing predicts favorable survival in microsatellite stable metastatic colon cancer patients
by: Annabella Di Mauro, et al.
Published: (2024-12-01) -
Correction To: High tumor mutational burden assessed through next‑generation sequencing predicts favorable survival in microsatellite stable metastatic colon cancer patients
by: Annabella Di Mauro, et al.
Published: (2025-01-01) -
Innovative Drug Modalities for the Treatment of Advanced Prostate Cancer
by: Maurizio Capuozzo, et al.
Published: (2024-05-01) -
An efficient transition-metal-free route to oligo-$\alpha $-pyridylamines via fluoroarenes
by: Nicolini, Alessio, et al.
Published: (2023-03-01) -
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)
by: Hua-Jun Chen, et al.
Published: (2025-01-01)